Ⅲ期胃癌术后过继TAK细胞免疫化疗的远期疗效  

Long-term Therapeutic Efficacy of Adoptive Immunotherapy with TAK Cells in Stage Ⅲ Gastric Carcinoma

作　　者：林镇和[1] 刘振华[1] 林孟波[1] 王清水[1] 崔同健[1] 陈晓耕[1] 

机构地区：[1]福建省立医院肿瘤科,福州350001

出　　处：《福建医科大学学报》2003年第3期309-310,313,共3页Journal of Fujian Medical University

基　　金：福建省科技厅医药卫生科技攻关计划资助项目 ( 96-Z-82 )

摘　　要：目的　观察 期胃癌术后过继肿瘤抗原激活的杀伤细胞 (TAK)免疫化疗的远期疗效。　方法　 5 7例 期胃癌患者随机分为 2组 ,即术后免疫化疗组 (A组 ,n=2 7)及术后单纯化疗组 (B组 ,n=30 ) ;统计比较 2组间1,2 ,3及 5年生存率差异及 T细胞亚群 CD3、CD4 、CD8、CD4 / CD8和 NK的变化。　结果　两组间 1,2 ,3及 5年生存率统计学差异有显著性 (P<0 .0 5 ) ,A组术后细胞免疫功能 CD3、CD4 、CD8、CD4 / CD8与治疗前比较差异有显著性 (P<0 .0 5 ) ,B组无差异。　结论　对胃癌术后免疫化疗 ,TAK细胞过继回输可提高患者的细胞免疫功能和生存率 。Objective\ To observe long\|term therapeutic efficacy of adoptive immunotherapy with tumor antigen activated killer(TAK) cells against stage Ⅲ gastric carcinoma.\ Methods\ 57 cases of stage Ⅲ gastric carcinoma were randomized into 2 groups, group A (n=27) received surgical resection followed immunochemotherapy with autologous TAK cells, and group B(n=30) received surgical resection followed chemotherapy only. The difference of survival rate(1, 2, 3 and 5 year) and cellular immunological function CD\-3, CD\-4, CD\-8, CD\-4/CD\-8, NK between 2 groups was analyzed statistically.\ Results\ There were significant statistic differences of survival rate(1, 2, 3 and 5 year) between two groups(P<0 05).\ The postoperative cellular immunological function of CD\-3, CD\-4, CD\-8, CD\-4/CD\-8 improved in group A(P<0 05) than in group B.\ Conclusion\ Adoptive infusion with TAK cells immunotherapy was confirmed to be one of the effective comprehensive therapeutic method against stage Ⅲ gastric carcinoma after surgical resection.\ It can increase cellular immunological function and survival rate of patients.

关 键 词：胃肿瘤 免疫疗法 过继 杀伤细胞 淋巴因子激活 

分 类 号：R735.2[医药卫生—肿瘤]